10-Q Filing
Filing Information
| Form Type | 10-Q |
| Accession Number | 0000950170-24-059587 |
| Period End Date | 20240331 |
| Filing Date | 20240514 |
| Fiscal Year | 2024 |
| Fiscal Period | Q1 |
| XBRL Instance | crgx-20240331_htm.xml |
Filing Contents
This filing contains the following financial statements:
Balance Sheet
92 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$58.77M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$58.77M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$405.73M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$405.73M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$81.53M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$81.53M | USD | Point-in-time |
| Marketable securities |
MarketableSecuritiesCurrent
|
$294.39M | USD | Point-in-time |
| Marketable securities |
MarketableSecuritiesCurrent
|
$294.39M | USD | Point-in-time |
| Prepaid expenses and other current assets |
PrepaidExpenseAndOtherAssetsCurrent
|
$3.75M | USD | Point-in-time |
| Prepaid expenses and other current assets |
PrepaidExpenseAndOtherAssetsCurrent
|
$3.75M | USD | Point-in-time |
| Prepaid expenses and other current assets |
PrepaidExpenseAndOtherAssetsCurrent
|
$4.04M | USD | Point-in-time |
| Prepaid expenses and other current assets |
PrepaidExpenseAndOtherAssetsCurrent
|
$4.04M | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$409.48M | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$409.48M | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$379.95M | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$379.95M | USD | Point-in-time |
| Operating lease right-of-use assets |
OperatingLeaseRightOfUseAsset
|
$28.22M | USD | Point-in-time |
| Operating lease right-of-use assets |
OperatingLeaseRightOfUseAsset
|
$28.22M | USD | Point-in-time |
| Operating lease right-of-use assets |
OperatingLeaseRightOfUseAsset
|
$26.92M | USD | Point-in-time |
| Operating lease right-of-use assets |
OperatingLeaseRightOfUseAsset
|
$26.92M | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$10.61M | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$10.61M | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$10.38M | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$10.38M | USD | Point-in-time |
| Other non-current assets |
OtherAssetsNoncurrent
|
$4.38M | USD | Point-in-time |
| Other non-current assets |
OtherAssetsNoncurrent
|
$4.38M | USD | Point-in-time |
| Other non-current assets |
OtherAssetsNoncurrent
|
$4.39M | USD | Point-in-time |
| Other non-current assets |
OtherAssetsNoncurrent
|
$4.39M | USD | Point-in-time |
| Total assets |
Assets
|
$422.43M | USD | Point-in-time |
| Total assets |
Assets
|
$422.43M | USD | Point-in-time |
| Total assets |
Assets
|
$453.04M | USD | Point-in-time |
| Total assets |
Assets
|
$453.04M | USD | Point-in-time |
| Accounts payable |
AccountsPayableCurrent
|
$5.01M | USD | Point-in-time |
| Accounts payable |
AccountsPayableCurrent
|
$5.01M | USD | Point-in-time |
| Accounts payable |
AccountsPayableCurrent
|
$7.17M | USD | Point-in-time |
| Accounts payable |
AccountsPayableCurrent
|
$7.17M | USD | Point-in-time |
| Accrued clinical and research and development expenses |
AccruedClinicalAndResearchAndDevelopmentExpensesCurrent
|
$10.46M | USD | Point-in-time |
| Accrued clinical and research and development expenses |
AccruedClinicalAndResearchAndDevelopmentExpensesCurrent
|
$10.46M | USD | Point-in-time |
| Accrued clinical and research and development expenses |
AccruedClinicalAndResearchAndDevelopmentExpensesCurrent
|
$7.24M | USD | Point-in-time |
| Accrued clinical and research and development expenses |
AccruedClinicalAndResearchAndDevelopmentExpensesCurrent
|
$7.24M | USD | Point-in-time |
| Accrued expenses and other current liabilities |
AccruedExpensesAndOtherCurrentLiabilities
|
$3.38M | USD | Point-in-time |
| Accrued expenses and other current liabilities |
AccruedExpensesAndOtherCurrentLiabilities
|
$3.38M | USD | Point-in-time |
| Accrued expenses and other current liabilities |
AccruedExpensesAndOtherCurrentLiabilities
|
$6.63M | USD | Point-in-time |
| Accrued expenses and other current liabilities |
AccruedExpensesAndOtherCurrentLiabilities
|
$6.63M | USD | Point-in-time |
| Operating lease liabilities, current |
OperatingLeaseLiabilityCurrent
|
$1.64M | USD | Point-in-time |
| Operating lease liabilities, current |
OperatingLeaseLiabilityCurrent
|
$1.64M | USD | Point-in-time |
| Operating lease liabilities, current |
OperatingLeaseLiabilityCurrent
|
$2.28M | USD | Point-in-time |
| Operating lease liabilities, current |
OperatingLeaseLiabilityCurrent
|
$2.28M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$21.16M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$21.16M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$22.65M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$22.65M | USD | Point-in-time |
| Operating lease liabilities, non-current |
OperatingLeaseLiabilityNoncurrent
|
$26.57M | USD | Point-in-time |
| Operating lease liabilities, non-current |
OperatingLeaseLiabilityNoncurrent
|
$26.57M | USD | Point-in-time |
| Operating lease liabilities, non-current |
OperatingLeaseLiabilityNoncurrent
|
$26.26M | USD | Point-in-time |
| Operating lease liabilities, non-current |
OperatingLeaseLiabilityNoncurrent
|
$26.26M | USD | Point-in-time |
| Other non-current liabilities |
OtherLiabilitiesNoncurrent
|
$225.00K | USD | Point-in-time |
| Other non-current liabilities |
OtherLiabilitiesNoncurrent
|
$225.00K | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$49.22M | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$49.22M | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$47.65M | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$47.65M | USD | Point-in-time |
| Common stock |
CommonStockValue
|
$39.00K | USD | Point-in-time |
| Common stock |
CommonStockValue
|
$39.00K | USD | Point-in-time |
| Common stock |
CommonStockValue
|
$41.00K | USD | Point-in-time |
| Common stock |
CommonStockValue
|
$41.00K | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$554.41M | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$554.41M | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$550.49M | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$550.49M | USD | Point-in-time |
| Accumulated other comprehensive loss |
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
$-279.00K | USD | Point-in-time |
| Accumulated other comprehensive loss |
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
$-279.00K | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-180.96M | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-180.96M | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-145.15M | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-145.15M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$-57.76M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$-57.76M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$-35.24M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$-35.24M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
| Total liabilities and stockholders' equity |
LiabilitiesAndStockholdersEquity
|
$422.43M | USD | Point-in-time |
| Total liabilities and stockholders' equity |
LiabilitiesAndStockholdersEquity
|
$422.43M | USD | Point-in-time |
| Total liabilities and stockholders' equity |
LiabilitiesAndStockholdersEquity
|
$453.04M | USD | Point-in-time |
| Total liabilities and stockholders' equity |
LiabilitiesAndStockholdersEquity
|
$453.04M | USD | Point-in-time |
Income Statement
58 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Research and development |
ResearchAndDevelopmentExpense
|
$12.56M | USD | 1 Quarter |
| Research and development |
ResearchAndDevelopmentExpense
|
$12.56M | USD | 1 Quarter |
| Research and development |
ResearchAndDevelopmentExpense
|
$30.50M | USD | 1 Quarter |
| Research and development |
ResearchAndDevelopmentExpense
|
$30.50M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$2.69M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$2.69M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$10.30M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$10.30M | USD | 1 Quarter |
| Total operating expenses |
OperatingExpenses
|
$15.25M | USD | 1 Quarter |
| Total operating expenses |
OperatingExpenses
|
$15.25M | USD | 1 Quarter |
| Total operating expenses |
OperatingExpenses
|
$40.81M | USD | 1 Quarter |
| Total operating expenses |
OperatingExpenses
|
$40.81M | USD | 1 Quarter |
| Loss from operations |
OperatingIncomeLoss
|
$-15.25M | USD | 1 Quarter |
| Loss from operations |
OperatingIncomeLoss
|
$-15.25M | USD | 1 Quarter |
| Loss from operations |
OperatingIncomeLoss
|
$-40.81M | USD | 1 Quarter |
| Loss from operations |
OperatingIncomeLoss
|
$-40.81M | USD | 1 Quarter |
| Interest income |
InvestmentIncomeInterest
|
$5.00M | USD | 1 Quarter |
| Interest income |
InvestmentIncomeInterest
|
$5.00M | USD | 1 Quarter |
| Interest income |
InvestmentIncomeInterest
|
$105.00K | USD | 1 Quarter |
| Interest income |
InvestmentIncomeInterest
|
$105.00K | USD | 1 Quarter |
| Interest expense |
InterestExpense
|
$1.60M | USD | 1 Quarter |
| Interest expense |
InterestExpense
|
$1.60M | USD | 1 Quarter |
| Net change in fair value of redeemable convertible preferred stock tranche obligations |
NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations
|
$58.00K | USD | 1 Quarter |
| Net change in fair value of redeemable convertible preferred stock tranche obligations |
NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations
|
$58.00K | USD | 1 Quarter |
| Change in fair value of derivative liabilities |
DerivativeGainLossOnDerivativeNet
|
$6.45M | USD | 1 Quarter |
| Change in fair value of derivative liabilities |
DerivativeGainLossOnDerivativeNet
|
$6.45M | USD | 1 Quarter |
| Loss on extinguishment of convertible notes |
GainsLossesOnExtinguishmentOfDebt
|
$-2.32M | USD | 1 Quarter |
| Loss on extinguishment of convertible notes |
GainsLossesOnExtinguishmentOfDebt
|
$-2.32M | USD | 1 Quarter |
| Other income (expense), net |
OtherNonoperatingIncomeExpense
|
$-80.00K | USD | 1 Quarter |
| Other income (expense), net |
OtherNonoperatingIncomeExpense
|
$-80.00K | USD | 1 Quarter |
| Other income (expense), net |
OtherNonoperatingIncomeExpense
|
$-10.00K | USD | 1 Quarter |
| Other income (expense), net |
OtherNonoperatingIncomeExpense
|
$-10.00K | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-12.75M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-12.75M | USD | 1 Quarter |
| Unrealized loss on marketable securities |
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
$-279.00K | USD | 1 Quarter |
| Unrealized loss on marketable securities |
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
$-279.00K | USD | 1 Quarter |
| Comprehensive loss |
ComprehensiveIncomeNetOfTax
|
$-12.75M | USD | 1 Quarter |
| Comprehensive loss |
ComprehensiveIncomeNetOfTax
|
$-12.75M | USD | 1 Quarter |
| Comprehensive loss |
ComprehensiveIncomeNetOfTax
|
$-36.09M | USD | 1 Quarter |
| Comprehensive loss |
ComprehensiveIncomeNetOfTax
|
$-36.09M | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, basic |
EarningsPerShareBasic
|
$-0.87 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, basic |
EarningsPerShareBasic
|
$-0.87 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, basic |
EarningsPerShareBasic
|
$-21.36 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, basic |
EarningsPerShareBasic
|
$-21.36 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, diluted |
EarningsPerShareDiluted
|
$-21.36 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, diluted |
EarningsPerShareDiluted
|
$-21.36 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, diluted |
EarningsPerShareDiluted
|
$-0.87 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, diluted |
EarningsPerShareDiluted
|
$-0.87 | USD | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
41.00M | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
41.00M | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
596,738.00 | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
596,738.00 | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
596,738.00 | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
596,738.00 | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
41.00M | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
41.00M | shares | 1 Quarter |
Cash Flow Statement
136 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-12.75M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-12.75M | USD | 1 Quarter |
| Stock-based compensation expense |
ShareBasedCompensation
|
$3.90M | USD | 1 Quarter |
| Stock-based compensation expense |
ShareBasedCompensation
|
$3.90M | USD | 1 Quarter |
| Stock-based compensation expense |
ShareBasedCompensation
|
$31.00K | USD | 1 Quarter |
| Stock-based compensation expense |
ShareBasedCompensation
|
$31.00K | USD | 1 Quarter |
| Amortization of operating lease right-of-use assets |
OperatingLeaseRightOfUseAssetAmortizationExpense
|
$470.00K | USD | 1 Quarter |
| Amortization of operating lease right-of-use assets |
OperatingLeaseRightOfUseAssetAmortizationExpense
|
$470.00K | USD | 1 Quarter |
| Amortization of operating lease right-of-use assets |
OperatingLeaseRightOfUseAssetAmortizationExpense
|
$1.30M | USD | 1 Quarter |
| Amortization of operating lease right-of-use assets |
OperatingLeaseRightOfUseAssetAmortizationExpense
|
$1.30M | USD | 1 Quarter |
| Depreciation |
Depreciation
|
$213.00K | USD | 1 Quarter |
| Depreciation |
Depreciation
|
$213.00K | USD | 1 Quarter |
| Depreciation |
Depreciation
|
$553.00K | USD | 1 Quarter |
| Depreciation |
Depreciation
|
$553.00K | USD | 1 Quarter |
| Acquired in-process research and development |
AcquiredInProcessResearchAndDevelopment
|
$465.00K | USD | 1 Quarter |
| Acquired in-process research and development |
AcquiredInProcessResearchAndDevelopment
|
$465.00K | USD | 1 Quarter |
| Acquired in-process research and development |
AcquiredInProcessResearchAndDevelopment
|
$150.00K | USD | 1 Quarter |
| Acquired in-process research and development |
AcquiredInProcessResearchAndDevelopment
|
$150.00K | USD | 1 Quarter |
| Net accretion on investments in marketable securities |
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
$2.33M | USD | 1 Quarter |
| Net accretion on investments in marketable securities |
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
$2.33M | USD | 1 Quarter |
| Change in fair value of derivative liabilities |
DerivativeGainLossOnDerivativeNet
|
$6.45M | USD | 1 Quarter |
| Change in fair value of derivative liabilities |
DerivativeGainLossOnDerivativeNet
|
$6.45M | USD | 1 Quarter |
| Loss on extinguishment of convertible notes |
GainsLossesOnExtinguishmentOfDebt
|
$-2.32M | USD | 1 Quarter |
| Loss on extinguishment of convertible notes |
GainsLossesOnExtinguishmentOfDebt
|
$-2.32M | USD | 1 Quarter |
| Noncash interest expense |
PaidInKindInterest
|
$1.60M | USD | 1 Quarter |
| Noncash interest expense |
PaidInKindInterest
|
$1.60M | USD | 1 Quarter |
| Net change in fair value of redeemable convertible preferred stock tranche obligations |
NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations
|
$58.00K | USD | 1 Quarter |
| Net change in fair value of redeemable convertible preferred stock tranche obligations |
NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations
|
$58.00K | USD | 1 Quarter |
| Prepaid expenses and other current assets |
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
$-969.00K | USD | 1 Quarter |
| Prepaid expenses and other current assets |
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
$-969.00K | USD | 1 Quarter |
| Prepaid expenses and other current assets |
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
$391.00K | USD | 1 Quarter |
| Prepaid expenses and other current assets |
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
$391.00K | USD | 1 Quarter |
| Other non-current assets |
IncreaseDecreaseInOtherNoncurrentAssets
|
$-10.00K | USD | 1 Quarter |
| Other non-current assets |
IncreaseDecreaseInOtherNoncurrentAssets
|
$-10.00K | USD | 1 Quarter |
| Other non-current assets |
IncreaseDecreaseInOtherNoncurrentAssets
|
$150.00K | USD | 1 Quarter |
| Other non-current assets |
IncreaseDecreaseInOtherNoncurrentAssets
|
$150.00K | USD | 1 Quarter |
| Accounts payable |
IncreaseDecreaseInAccountsPayable
|
$-2.70M | USD | 1 Quarter |
| Accounts payable |
IncreaseDecreaseInAccountsPayable
|
$-2.70M | USD | 1 Quarter |
| Accounts payable |
IncreaseDecreaseInAccountsPayable
|
$2.67M | USD | 1 Quarter |
| Accounts payable |
IncreaseDecreaseInAccountsPayable
|
$2.67M | USD | 1 Quarter |
| Accrued clinical and research and development expenses |
IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses
|
$2.97M | USD | 1 Quarter |
| Accrued clinical and research and development expenses |
IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses
|
$2.97M | USD | 1 Quarter |
| Accrued clinical and research and development expenses |
IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses
|
$3.27M | USD | 1 Quarter |
| Accrued clinical and research and development expenses |
IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses
|
$3.27M | USD | 1 Quarter |
| Accrued expenses and other current liabilities |
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
$-3.15M | USD | 1 Quarter |
| Accrued expenses and other current liabilities |
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
$-3.15M | USD | 1 Quarter |
| Accrued expenses and other current liabilities |
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
$-758.00K | USD | 1 Quarter |
| Accrued expenses and other current liabilities |
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
$-758.00K | USD | 1 Quarter |
| Operating lease liabilities |
IncreaseDecreaseInOperatingLeaseLiability
|
$-336.00K | USD | 1 Quarter |
| Operating lease liabilities |
IncreaseDecreaseInOperatingLeaseLiability
|
$-336.00K | USD | 1 Quarter |
| Operating lease liabilities |
IncreaseDecreaseInOperatingLeaseLiability
|
$-351.00K | USD | 1 Quarter |
| Operating lease liabilities |
IncreaseDecreaseInOperatingLeaseLiability
|
$-351.00K | USD | 1 Quarter |
| Net cash used in operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$-14.06M | USD | 1 Quarter |
| Net cash used in operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$-14.06M | USD | 1 Quarter |
| Net cash used in operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$-30.15M | USD | 1 Quarter |
| Net cash used in operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$-30.15M | USD | 1 Quarter |
| Purchases of marketable securities |
PaymentsToAcquireMarketableSecurities
|
$292.34M | USD | 1 Quarter |
| Purchases of marketable securities |
PaymentsToAcquireMarketableSecurities
|
$292.34M | USD | 1 Quarter |
| Purchase of property and equipment |
PaymentsToAcquireProductiveAssets
|
$561.00K | USD | 1 Quarter |
| Purchase of property and equipment |
PaymentsToAcquireProductiveAssets
|
$561.00K | USD | 1 Quarter |
| Purchase of property and equipment |
PaymentsToAcquireProductiveAssets
|
$1.29M | USD | 1 Quarter |
| Purchase of property and equipment |
PaymentsToAcquireProductiveAssets
|
$1.29M | USD | 1 Quarter |
| Purchase of in-process research and development |
PaymentsToAcquireInProcessResearchAndDevelopment
|
$58.00K | USD | 1 Quarter |
| Purchase of in-process research and development |
PaymentsToAcquireInProcessResearchAndDevelopment
|
$58.00K | USD | 1 Quarter |
| Purchase of in-process research and development |
PaymentsToAcquireInProcessResearchAndDevelopment
|
$330.00K | USD | 1 Quarter |
| Purchase of in-process research and development |
PaymentsToAcquireInProcessResearchAndDevelopment
|
$330.00K | USD | 1 Quarter |
| Net cash used in investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$-619.00K | USD | 1 Quarter |
| Net cash used in investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$-619.00K | USD | 1 Quarter |
| Net cash used in investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$-293.96M | USD | 1 Quarter |
| Net cash used in investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$-293.96M | USD | 1 Quarter |
| Proceeds from issuance of convertible notes, net of issuance costs - related party |
ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCostsFromRelatedParty
|
$2.21M | USD | 1 Quarter |
| Proceeds from issuance of convertible notes, net of issuance costs - related party |
ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCostsFromRelatedParty
|
$2.21M | USD | 1 Quarter |
| Proceeds from issuance of convertible notes, net of issuance costs |
ProceedsFromDebtNetOfIssuanceCosts
|
$1.29M | USD | 1 Quarter |
| Proceeds from issuance of convertible notes, net of issuance costs |
ProceedsFromDebtNetOfIssuanceCosts
|
$1.29M | USD | 1 Quarter |
| Proceeds from issuance of redeemable convertible preferred stock and tranche obligations, net of issuance costs |
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndTrancheObligationsNetOfIssuanceCosts
|
$68.08M | USD | 1 Quarter |
| Proceeds from issuance of redeemable convertible preferred stock and tranche obligations, net of issuance costs |
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndTrancheObligationsNetOfIssuanceCosts
|
$68.08M | USD | 1 Quarter |
| Proceeds from exercise of stock options |
ProceedsFromStockOptionsExercised
|
$26.00K | USD | 1 Quarter |
| Proceeds from exercise of stock options |
ProceedsFromStockOptionsExercised
|
$26.00K | USD | 1 Quarter |
| Payment of deferred initial public offering costs |
PaymentsOfStockIssuanceCosts
|
$105.00K | USD | 1 Quarter |
| Payment of deferred initial public offering costs |
PaymentsOfStockIssuanceCosts
|
$105.00K | USD | 1 Quarter |
| Payment of transaction costs for exchange of common stock for warrants |
PaymentOfTransactionCostsForExchangeOfCommonStockForWarrants
|
$25.00K | USD | 1 Quarter |
| Payment of transaction costs for exchange of common stock for warrants |
PaymentOfTransactionCostsForExchangeOfCommonStockForWarrants
|
$25.00K | USD | 1 Quarter |
| Net cash (used in) provided by financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$71.58M | USD | 1 Quarter |
| Net cash (used in) provided by financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$71.58M | USD | 1 Quarter |
| Net cash (used in) provided by financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$-104.00K | USD | 1 Quarter |
| Net cash (used in) provided by financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$-104.00K | USD | 1 Quarter |
| Net (decrease) increase in cash, cash equivalents and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$-324.21M | USD | 1 Quarter |
| Net (decrease) increase in cash, cash equivalents and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$-324.21M | USD | 1 Quarter |
| Net (decrease) increase in cash, cash equivalents and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$56.89M | USD | 1 Quarter |
| Net (decrease) increase in cash, cash equivalents and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$56.89M | USD | 1 Quarter |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$406.30M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$406.30M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$1.87M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$1.87M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$82.09M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$82.09M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$58.77M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$58.77M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$406.30M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$406.30M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$1.87M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$1.87M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$82.09M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$82.09M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$58.77M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$58.77M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$58.77M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$58.77M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$405.73M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$405.73M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$81.53M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$81.53M | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$82.09M | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$82.09M | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$58.77M | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$58.77M | USD | Point-in-time |
| Exchange of common stock for pre-funded warrants |
ExchangeOfCommonStockForPrefundedWarrants
|
$37.60M | USD | 1 Quarter |
| Exchange of common stock for pre-funded warrants |
ExchangeOfCommonStockForPrefundedWarrants
|
$37.60M | USD | 1 Quarter |
| Conversion of convertible notes to shares of Series A-2 redeemable convertible preferred stock |
ConversionOfConvertibleNotesToSharesOfSeriesA2RedeemableConvertiblePreferredStock
|
$35.58M | USD | 1 Quarter |
| Conversion of convertible notes to shares of Series A-2 redeemable convertible preferred stock |
ConversionOfConvertibleNotesToSharesOfSeriesA2RedeemableConvertiblePreferredStock
|
$35.58M | USD | 1 Quarter |
| Reclassification of shares of Series Seed redeemable convertible preferred stock to mezzanine equity |
ReclassificationOfSharesOfSeriesSeedRedeemableConvertiblePreferredStockToMezzanineEquity
|
$9.83M | USD | 1 Quarter |
| Reclassification of shares of Series Seed redeemable convertible preferred stock to mezzanine equity |
ReclassificationOfSharesOfSeriesSeedRedeemableConvertiblePreferredStockToMezzanineEquity
|
$9.83M | USD | 1 Quarter |
| Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities |
CapitalExpendituresIncurredButNotYetPaid
|
$379.00K | USD | 1 Quarter |
| Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities |
CapitalExpendituresIncurredButNotYetPaid
|
$379.00K | USD | 1 Quarter |
| Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities |
CapitalExpendituresIncurredButNotYetPaid
|
$1.05M | USD | 1 Quarter |
| Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities |
CapitalExpendituresIncurredButNotYetPaid
|
$1.05M | USD | 1 Quarter |
| In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities |
InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities
|
$993.00K | USD | 1 Quarter |
| In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities |
InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities
|
$993.00K | USD | 1 Quarter |
| In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities |
InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities
|
$790.00K | USD | 1 Quarter |
| In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities |
InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities
|
$790.00K | USD | 1 Quarter |
Stockholders Equity
46 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Beginning balance, shares |
TemporaryEquitySharesOutstanding
|
0.00 | shares | Point-in-time |
| Beginning balance, shares |
TemporaryEquitySharesOutstanding
|
0.00 | shares | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$-57.76M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$-57.76M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$-35.24M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$-35.24M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
| Exchange of common stock for pre-funded warrants, value |
ExchangeOfCommonStockForPrefundedWarrantsValue
|
$25.00K | USD | 1 Quarter |
| Exchange of common stock for pre-funded warrants, value |
ExchangeOfCommonStockForPrefundedWarrantsValue
|
$25.00K | USD | 1 Quarter |
| Reclassification of series seed redeemable convertible preferred stock, amount |
ReclassificationOfSeriesSeedRedeemableConvertiblePreferredStockValue
|
$-9.83M | USD | 1 Quarter |
| Reclassification of series seed redeemable convertible preferred stock, amount |
ReclassificationOfSeriesSeedRedeemableConvertiblePreferredStockValue
|
$-9.83M | USD | 1 Quarter |
| Issuance of restricted stock, shares |
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
|
1,874.00 | shares | 1 Quarter |
| Issuance of restricted stock, shares |
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
|
1,874.00 | shares | 1 Quarter |
| Issuance of restricted stock, shares |
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
|
- | shares | 1 Quarter |
| Issuance of restricted stock, shares |
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
|
- | shares | 1 Quarter |
| Exercise of stock options, shares |
StockIssuedDuringPeriodSharesStockOptionsExercised
|
5,595.00 | shares | 1 Quarter |
| Exercise of stock options, shares |
StockIssuedDuringPeriodSharesStockOptionsExercised
|
5,595.00 | shares | 1 Quarter |
| Exercise of stock options, amount |
StockIssuedDuringPeriodValueStockOptionsExercised
|
$26.00K | USD | 1 Quarter |
| Exercise of stock options, amount |
StockIssuedDuringPeriodValueStockOptionsExercised
|
$26.00K | USD | 1 Quarter |
| Vesting of restricted stock |
VestingOfRestrictedStockAwardValue
|
$18.00K | USD | 1 Quarter |
| Vesting of restricted stock |
VestingOfRestrictedStockAwardValue
|
$18.00K | USD | 1 Quarter |
| Vesting of restricted stock |
VestingOfRestrictedStockAwardValue
|
$11.00K | USD | 1 Quarter |
| Vesting of restricted stock |
VestingOfRestrictedStockAwardValue
|
$11.00K | USD | 1 Quarter |
| Stock-based compensation |
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
$3.90M | USD | 1 Quarter |
| Stock-based compensation |
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
$3.90M | USD | 1 Quarter |
| Stock-based compensation |
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
$31.00K | USD | 1 Quarter |
| Stock-based compensation |
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
$31.00K | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-12.75M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-12.75M | USD | 1 Quarter |
| Other comprehensive loss |
OtherComprehensiveIncomeLossNetOfTax
|
$-279.00K | USD | 1 Quarter |
| Other comprehensive loss |
OtherComprehensiveIncomeLossNetOfTax
|
$-279.00K | USD | 1 Quarter |
| Ending balance, shares |
TemporaryEquitySharesOutstanding
|
0.00 | shares | Point-in-time |
| Ending balance, shares |
TemporaryEquitySharesOutstanding
|
0.00 | shares | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$-57.76M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$-57.76M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$-35.24M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$-35.24M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.